WallStreetZenWallStreetZen

NASDAQ: GLUE
Monte Rosa Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for GLUE

Based on 1 analyst offering 12 month price targets for Monte Rosa Therapeutics Inc.
Min Forecast
$11.00+166.99%
Avg Forecast
$11.00+166.99%
Max Forecast
$11.00+166.99%

Should I buy or sell GLUE stock?

Based on 1 analyst offering ratings for Monte Rosa Therapeutics Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their GLUE stock forecasts and price targets.

GLUE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-05-22

1 of 1

Forecast return on equity

Is GLUE forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
27.86%

Forecast return on assets

Is GLUE forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

GLUE revenue forecast

What is GLUE's revenue in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
$9.1M+751.22%
Avg 2 year Forecast
$12.8M+1,104.23%
Avg 3 year Forecast
$24.9M+2,238.35%
GLUE's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

GLUE revenue growth forecast

How is GLUE forecast to perform vs Biotechnology companies and vs the US market?
Company
180.31%
Industry
35.39%
Market
9.64%
GLUE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
GLUE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

GLUE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GLUE$4.12$11.00+166.99%Buy
CDXC$2.76$6.00+117.39%Strong Buy
CHRS$1.82$9.33+412.80%Strong Buy
PRLD$3.85$5.33+38.52%Hold
GBIO$3.18$7.50+135.85%Buy
View Top Biotech Stocks

Monte Rosa Therapeutics Stock Forecast FAQ

Is Monte Rosa Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: GLUE) stock is to Buy GLUE stock.

Out of 1 analyst, 0 (0%) are recommending GLUE as a Strong Buy, 1 (100%) are recommending GLUE as a Buy, 0 (0%) are recommending GLUE as a Hold, 0 (0%) are recommending GLUE as a Sell, and 0 (0%) are recommending GLUE as a Strong Sell.

If you're new to stock investing, here's how to buy Monte Rosa Therapeutics stock.

What is GLUE's revenue growth forecast for 2024-2026?

(NASDAQ: GLUE) Monte Rosa Therapeutics's forecast annual revenue growth rate of 180.31% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.39%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.64%.

Monte Rosa Therapeutics's revenue in 2024 is $1,064,000.On average, 4 Wall Street analysts forecast GLUE's revenue for 2024 to be $457,487,356, with the lowest GLUE revenue forecast at $55,563,221, and the highest GLUE revenue forecast at $842,035,357. On average, 3 Wall Street analysts forecast GLUE's revenue for 2025 to be $647,210,499, with the lowest GLUE revenue forecast at $202,048,076, and the highest GLUE revenue forecast at $897,598,578.

In 2026, GLUE is forecast to generate $1,256,739,033 in revenue, with the lowest revenue forecast at $842,035,357 and the highest revenue forecast at $2,030,583,164.

What is GLUE's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: GLUE) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is GLUE's Price Target?

According to 1 Wall Street analyst that have issued a 1 year GLUE price target, the average GLUE price target is $11.00, with the highest GLUE stock price forecast at $11.00 and the lowest GLUE stock price forecast at $11.00.

The Wall Street analyst predicted that Monte Rosa Therapeutics's share price could reach $11.00 by May 22, 2025. The average Monte Rosa Therapeutics stock price prediction forecasts a potential upside of 166.99% from the current GLUE share price of $4.12.

What is GLUE's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: GLUE) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.